Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 在18岁及以上成年人中开展的新型冠状病毒mRNA疫苗安全性和免疫原性的随机、盲法、剂量探索、安慰剂对照的多中心Ⅰ期临床试验
[Translation] A randomized, blinded, dose-finding, placebo-controlled, multicenter Phase I clinical trial of the safety and immunogenicity of a novel coronavirus mRNA vaccine in adults aged 18 years and above
评价18岁及以上人群接种新型冠状病毒mRNA疫苗的安全性,初步评价免疫原性。
[Translation] Evaluate the safety of new coronavirus mRNA vaccine in people aged 18 years and above, and preliminarily evaluate the immunogenicity.
/ Not yet recruitingPhase 2 在18岁及以上成人中评价新型冠状病毒mRNA疫苗免疫原性和安全性的随机、盲法、剂量探索、安慰剂对照的多中心Ⅱ期临床试验
[Translation] A randomized, blinded, dose-finding, placebo-controlled, multicenter phase II clinical trial to evaluate the immunogenicity and safety of a novel coronavirus mRNA vaccine in adults aged 18 years and above
评价18岁及以上人群接种2剂新型冠状病毒mRNA疫苗的安全性和免疫原性。
[Translation] To evaluate the safety and immunogenicity of two doses of SARS-CoV-2 mRNA vaccine in people aged 18 years and above.
100 Clinical Results associated with Kangxinuo Biology (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Kangxinuo Biology (Shanghai) Co., Ltd.
100 Deals associated with Kangxinuo Biology (Shanghai) Co., Ltd.
100 Translational Medicine associated with Kangxinuo Biology (Shanghai) Co., Ltd.